EGFR and non-small cell lung carcinoma: The mechanisms underlying EGFR–TKI resistance in NSCLC can be broadly categorized into acquired resistance following EGFR–TKI treatment and primary resistance characterized by cancer cells relying on alternative oncogenes like KRAS.